Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

Gentian Diagnostics

Less than 1K followers

GENT

Oslo Børs

Medical Equipment & Services

Health Care

Overview
Investor consensus

Gentian Diagnostics is a medical diagnostics company that develops and manufactures in vitro diagnostic reagents for high-throughput analyzers. Gentian's expertise and focus lies in homogeneous immunoassays, specifically infections, inflammation, renal failure and congestive heart failure. The company's headquarters and production facilities are located in Moss, Norway, and serves the global human and veterinary diagnostics market through sales and representative offices in a number of key countries.

Read more
Market cap
-
Turnover
-
Revenue
176.5M
EBIT %
14.42 %
P/E
-
Dividend yield-%
-
Financial calendar
5.5
2026

General meeting '26

6.5
2026

Interim report Q1'26

6.5
2026

Annual dividend

All
Press releases
ShowingAll content types
Regulatory press release13 hours ago

Gentian Diagnostics ASA - Registration of share capital increase

Gentian Diagnostics
Regulatory press release3/20/2026, 7:36 AM

Gentian Diagnostics: Annual report 2025

Gentian Diagnostics
Regulatory press release3/12/2026, 9:36 AM

Gentian Diagnostics ASA - Mandatory notification of subscription of shares by primary insiders in Employee Share Purchase Program

Gentian Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/12/2026, 9:36 AM

Gentian Diagnostics ASA - Employee Share Purchase Program and share capital increase

Gentian Diagnostics
Regulatory press release2/19/2026, 9:21 AM

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release2/13/2026, 8:26 AM

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release2/12/2026, 3:09 PM

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release2/12/2026, 8:49 AM

Gentian Diagnostics: Key information relating to the proposed cash dividend

Gentian Diagnostics
Regulatory press release2/11/2026, 7:23 AM

GENT: Update on the development of the NT-proBNP assay

Gentian Diagnostics
Regulatory press release2/11/2026, 7:19 AM

Gentian Diagnostics: Fourth quarter 2025 report

Gentian Diagnostics
Regulatory press release2/4/2026, 7:22 AM

Gentian Diagnostics: Invitation to presentation of fourth quarter results

Gentian Diagnostics
Regulatory press release1/28/2026, 1:38 PM

GENT: Gentian Diagnostics invites to NT-proBNP educational webinar

Gentian Diagnostics
Regulatory press release1/7/2026, 9:04 AM

GENT: Gentian Diagnostics announces exclusive partnership for the development of a novel diagnostic assay with a leading global IVD company

Gentian Diagnostics
Regulatory press release12/18/2025, 8:06 AM

Gentian Diagnostics: Update on NT-proBNP

Gentian Diagnostics
Regulatory press release11/25/2025, 7:10 AM

GENT: Gentian Diagnostics presents at the DNB Nordic Healthcare Conference

Gentian Diagnostics
Regulatory press release11/11/2025, 10:32 AM

GENT: Financial calendar

Gentian Diagnostics
Regulatory press release10/28/2025, 7:41 AM

GENT: Mandatory notification of trade

Gentian Diagnostics
Regulatory press release10/23/2025, 8:15 AM

Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detection of Neonatal Infections and Sepsis

Gentian Diagnostics
Regulatory press release10/23/2025, 6:00 AM

Gentian Diagnostics: Third quarter 2025 report

Gentian Diagnostics
Regulatory press release10/16/2025, 7:55 AM

Gentian Diagnostics: Invitation to presentation of third quarter results

Gentian Diagnostics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.